Quantcast

Latest H5N1 clinical trials Stories

2009-12-01 07:00:00

BEIJING, Dec. 1 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that it has received its fourth purchase order for its H1N1 vaccine, PANFLU.1(TM), from China's Ministry of Industry and Information Technology for the national purchase plan. Under this purchase order, Sinovac is required to produce an additional one million doses of PANFLU.1 (TM) (15ug/0.5ml) for the Chinese central government. The delivery of...

2009-11-30 07:05:00

ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal...

6398326d01aed6b3956ff4571c196d5a1
2009-11-24 12:52:40

The WHO said on Tuesday that GlaxoSmithKline recalled a batch of swine flu vaccine in Canada after a number of severe allergic reactions surfaced, The Associated Press reported. The recall was issued after reports that one batch of the swine flu vaccine might have caused more allergic reactions than normal, according to company spokeswoman Gwenan White. White said GlaxoSmithKline advised health care professionals not to use the batch while health authorities investigate. However, the batch in...

89cdb83d08f3bae5bc694b94b65392e81
2009-11-24 06:00:00

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) on Monday voiced concerns about the sluggish vaccination rate for the H1N1 swine flu due to public skepticism over health risks and side effects. "ESCMID joins others concerned about the lack of uptake due to both public skepticism and deliberate misinformation being raised by a growing anti-vaccination movement in a number of countries," the group said in a statement. "It is feared a low uptake of the vaccine...

2009-11-16 07:00:00

ROCKVILLE, Md., Nov. 16 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country of Mexico. An independent data and safety monitoring board has reviewed preliminary safety data from the first half of this cohort and recommended that this first stage continue as planned. The study is being...

2009-11-11 13:00:00

SWIFTWATER, Pa., Nov. 11 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today the final analyses of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in adults and children. To view the Multimedia News Release, go to: http://multivu.prnewswire.com/mnr/sanofi_pasteur/41122/ The data confirm the immunogenicity and safety profile of the vaccine, with no serious...

2009-11-11 09:30:00

ROCKVILLE, Md., Nov. 11 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that John Trizzino, Senior Vice President, International and Government Alliances, will be presenting at the Influenza Congress USA 2009. Mr. Trizzino's presentation will take place at 3:30 pm local time on November 20, 2009 at The Westin Washington, Washington D.C. Mr. Trizzino will be discussing regional partnership drivers, benefits of regional partnerships...

2009-11-10 07:00:00

ROCKVILLE, Md., Nov. 10 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) has begun a Phase IIa clinical study of its trivalent seasonal influenza VLP vaccine candidate in healthy adults 60 years of age or older. This randomized, double-blind, active-controlled study is evaluating the safety, tolerability and immunogenicity of two different doses of Novavax's trivalent seasonal influenza VLP vaccine compared with that of a commercially available trivalent inactivated vaccine (TIV,...

2009-11-05 06:53:00

GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This four-year contract has a total value of over $22 million if all options are exercised. Over the next year, GenVec will...

2009-11-03 14:08:36

Pivotal testing of RTS,S is on track for target enrollment of 16,000 children A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced Tuesday at the 5th Multilateral Initiative on Malaria...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related